All In Biotech

Drug Trial Radar · NCT06736938

Balanced Analgosedation in Bronchoscopy: Propofol/Pethidine Versus Midazolam/Pethidine

Efficacy and Safety of Balanced Analgosedation in Bronchoscopy With Propofol/Pethidine Versus Midazolam/Pethidine: a Single-centre Randomised Controlled Trial

Last checked: Nov 20, 2026Latest source record: Dec 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 530 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

530

Planned (sponsor's estimate)

Start

Apr 1, 2025

Primary completion

Apr 1, 2027

Study completion Apr 1, 2027

Sponsor

Lead sponsor
Fondazione Andrea Cesalpino Arezzo ONLUSAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Azienda USL Toscana Sud Est; Ospedale San Donato, Arezzo
First posted
Dec 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare the safety and efficacy of two pharmacological sedation regimens during bronchoscopy procedures in adult patients who require elective bronchoscopy. The main questions it aims to answer are: * Is propofol/pethidine analgesia administered by a pulmonologist as effective and safe as midazolam/pethidine in achieving adequate sedation during bronchoscopy, particularly in terms of desaturation rate? * Does the choice of sedative (midazolam vs. propofol) influence the occurrence of adverse events or need for escalated care?

Conditions

  • Sedation During Bronchoscopy

Interventions

  • Propofol 1%Drug

    Propofol 1% is infused intravenously, initially at a bolus dose of 0.5 mg/kg followed by a maintenance dose in a continuous infusion of 0.5-1.0 mg/kg/hour.

  • MidazolamDrug

    Midazolam is administered intravenously at an initial dose of 2 mg, as a bolus, followed by aliquots of 0.5 mg or 1 mg.

  • PethidineDrug

    Pethidine (100 mg/2 ml) is administered intravenously at a dosage of 0.5 mg/kg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Desaturation IndexTime frame: Trough study completion, an average of 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • San Donato Hospital

    Arezzo, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.